中文产业新闻评分64Chinese source
药友制药BCMA×CD3双抗纬利妥米单抗获NMPA附条件批准，治疗三线后复发难治性多发性骨髓瘤
药友制药：首个国产原研BCMA×CD3双抗纬利妥米单抗获批上市,复发难治性多发性骨髓瘤患者迎来新希望！
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
药友制药：首个国产原研BCMA×CD3双抗纬利妥米单抗获批上市,复发难治性多发性骨髓瘤患者迎来新希望！
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.